Great article, would you like

1
Comment
Favorite

Great article, would you like to share it?

Eli Lilly’s Stock Has Crushed Nvidia’s in Recent Weeks. What History Has to Say About That

‘History suggests Nvidia should modestly beat Eli Lilly over the next roughly two months,’ notes a DataTrek analyst — but there are some caveats.

Eli Lilly’s Stock Has Crushed Nvidia’s in Recent Weeks. What History Has to Say About That

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Top
Latest

No comments yet

Most Discussed

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":512055821468104,"tweetId":"512055821468104","gmtCreate":1766041263641,"gmtModify":1766041267323,"author":{"id":4154261456187952,"idStr":"4154261456187952","authorId":4154261456187952,"authorIdStr":"4154261456187952","name":"Stephanie Lai","avatar":"https://community-static.tradeup.com/news/7539f808760ddf3a151b24618cddb75f","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"currentWearingBadge":{"badgeId":"23f878ed27704312ae41c7f17e73b319-5","templateUuid":"23f878ed27704312ae41c7f17e73b319","name":"Annualised return","description":"Top 5%","bigImgUrl":"https://community-static.tradeup.com/news/28b025635697d2f8cba3e94ec9f33231","smallImgUrl":"https://community-static.tradeup.com/news/b9d0f04877ffafa61d3f0d06efb58d87","grayImgUrl":"https://community-static.tradeup.com/news/0b3045db9a2ba37916c82e771c62bd6c","redirectLinkEnabled":0,"redirectLink":"https://www.tigerbrokers.com.sg/activity/market/2023/stock-contest?adcode=StockContest2023","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.09.12","individualDisplayEnabled":0},"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body><p>Great article, would you like to share it?</p></body></html>","htmlText":"<html><head></head><body><p>Great article, would you like to share it?</p></body></html>","text":"Great article, would you like to share it?","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/512055821468104","repostId":2592158910,"repostType":2,"repost":{"id":"2592158910","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1766041200,"share":"https://ttm.financial/m/news/2592158910?lang=en_US&edition=fundamental","pubTime":"2025-12-18 15:00","market":"us","language":"en","title":"Eli Lilly’s Stock Has Crushed Nvidia’s in Recent Weeks. What History Has to Say About That","url":"https://stock-news.laohu8.com/highlight/detail?id=2592158910","media":"Dow Jones","summary":"‘History suggests Nvidia should modestly beat Eli Lilly over the next roughly two months,’ notes a DataTrek analyst — but there are some caveats.","content":"<html><head></head><body><p style=\"text-align: start;\">The recent rotation into healthcare stocks and out of hot technology plays can be epitomized by the strong outperformance of Eli Lilly shares relative to Nvidia’s stock.</p><p style=\"text-align: start;\">Since the tech sector peaked on Oct. 29, <a href=\"https://laohu8.com/S/LLY\">Lilly</a>’s stock has climbed about 30%, while <a href=\"https://laohu8.com/S/NVDA\">Nvidia</a>’s has lost roughly 14%.</p><p>DataTrek co-founder Jessica Rabe expanded upon the trend in a Wednesday note — mentioning that on Nov. 25, Eli Lilly’s 50-day return exceeded Nvidia’s by 43.5 basis points, or more than two standard deviations away from the long-term average. That’s only happened on 1.5% of trading days going back to 2010.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/9ccda73999aa82d9ea1aa625710de152\" title=\"\" tg-width=\"971\" tg-height=\"701\"/></p><p>For Nvidia investors, it’s a potentially hopeful sign — with some caveats. “When Eli Lilly has beaten Nvidia by more than two standard deviations over any given 50-day period since 2010, the latter has gone on to outperform by an average of 2.3 points over the next 50 days,” Rabe wrote.</p><p style=\"text-align: start;\">But she cautioned that her observation was meant more to illustrate the “extreme rotation” out of the tech sector, and not to serve as a buy recommendation on Nvidia’s stock.</p><p style=\"text-align: start;\">After all, “history suggests Nvidia should modestly beat Eli Lilly over the next roughly two months, but bear in mind the chances of [Nvidia] outperforming is less than a coin flip historically,” she noted — as the actual win rate for Nvidia, when looking at instances where there was a positive forward 50-date return on a relative basis, has only been 44% since the start of 2010.</p><p>Rabe also examined the recent performance of the broader healthcare sector versus the broader tech sector. Zooming out, she flagged the healthcare sector’s “highly unusual” outperformance by more than two standard deviations, which also occurred on Nov. 25. In historical instances where that dynamic unfolded, the tech sector went on to deliver 11.3 points worth of outperformance in the following 50 days.</p><p style=\"text-align: start;\">“History strongly suggests U.S. large-cap healthcare is overbought relative to tech and the latter should outperform over the next roughly two months,” Rabe noted. While trends didn’t play out that way back in 2022, she implied the ongoing interest-rate-cutting cycle could benefit tech stocks nowadays.</p><p style=\"text-align: start;\">Wednesday’s price action, however, highlights a continuation of tech underperformance spurred by concerns about the health of the AI trade. Eli Lilly’s stock was off more than 1% in afternoon action, while Nvidia’s was down more than 3%.</p><p style=\"text-align: start;\">Eli Lilly’s stock has also topped Nvidia’s on a year-to-date basis, with the pharmaceutical company’s stock gaining 35% versus the chip maker’s 27% rise.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eli Lilly’s Stock Has Crushed Nvidia’s in Recent Weeks. What History Has to Say About That</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEli Lilly’s Stock Has Crushed Nvidia’s in Recent Weeks. What History Has to Say About That\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-18 15:00</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p style=\"text-align: start;\">The recent rotation into healthcare stocks and out of hot technology plays can be epitomized by the strong outperformance of Eli Lilly shares relative to Nvidia’s stock.</p><p style=\"text-align: start;\">Since the tech sector peaked on Oct. 29, <a href=\"https://laohu8.com/S/LLY\">Lilly</a>’s stock has climbed about 30%, while <a href=\"https://laohu8.com/S/NVDA\">Nvidia</a>’s has lost roughly 14%.</p><p>DataTrek co-founder Jessica Rabe expanded upon the trend in a Wednesday note — mentioning that on Nov. 25, Eli Lilly’s 50-day return exceeded Nvidia’s by 43.5 basis points, or more than two standard deviations away from the long-term average. That’s only happened on 1.5% of trading days going back to 2010.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/9ccda73999aa82d9ea1aa625710de152\" title=\"\" tg-width=\"971\" tg-height=\"701\"/></p><p>For Nvidia investors, it’s a potentially hopeful sign — with some caveats. “When Eli Lilly has beaten Nvidia by more than two standard deviations over any given 50-day period since 2010, the latter has gone on to outperform by an average of 2.3 points over the next 50 days,” Rabe wrote.</p><p style=\"text-align: start;\">But she cautioned that her observation was meant more to illustrate the “extreme rotation” out of the tech sector, and not to serve as a buy recommendation on Nvidia’s stock.</p><p style=\"text-align: start;\">After all, “history suggests Nvidia should modestly beat Eli Lilly over the next roughly two months, but bear in mind the chances of [Nvidia] outperforming is less than a coin flip historically,” she noted — as the actual win rate for Nvidia, when looking at instances where there was a positive forward 50-date return on a relative basis, has only been 44% since the start of 2010.</p><p>Rabe also examined the recent performance of the broader healthcare sector versus the broader tech sector. Zooming out, she flagged the healthcare sector’s “highly unusual” outperformance by more than two standard deviations, which also occurred on Nov. 25. In historical instances where that dynamic unfolded, the tech sector went on to deliver 11.3 points worth of outperformance in the following 50 days.</p><p style=\"text-align: start;\">“History strongly suggests U.S. large-cap healthcare is overbought relative to tech and the latter should outperform over the next roughly two months,” Rabe noted. While trends didn’t play out that way back in 2022, she implied the ongoing interest-rate-cutting cycle could benefit tech stocks nowadays.</p><p style=\"text-align: start;\">Wednesday’s price action, however, highlights a continuation of tech underperformance spurred by concerns about the health of the AI trade. Eli Lilly’s stock was off more than 1% in afternoon action, while Nvidia’s was down more than 3%.</p><p style=\"text-align: start;\">Eli Lilly’s stock has also topped Nvidia’s on a year-to-date basis, with the pharmaceutical company’s stock gaining 35% versus the chip maker’s 27% rise.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","NVDA":"英伟达"},"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2592158910","content_text":"The recent rotation into healthcare stocks and out of hot technology plays can be epitomized by the strong outperformance of Eli Lilly shares relative to Nvidia’s stock.Since the tech sector peaked on Oct. 29, Lilly’s stock has climbed about 30%, while Nvidia’s has lost roughly 14%.DataTrek co-founder Jessica Rabe expanded upon the trend in a Wednesday note — mentioning that on Nov. 25, Eli Lilly’s 50-day return exceeded Nvidia’s by 43.5 basis points, or more than two standard deviations away from the long-term average. That’s only happened on 1.5% of trading days going back to 2010.For Nvidia investors, it’s a potentially hopeful sign — with some caveats. “When Eli Lilly has beaten Nvidia by more than two standard deviations over any given 50-day period since 2010, the latter has gone on to outperform by an average of 2.3 points over the next 50 days,” Rabe wrote.But she cautioned that her observation was meant more to illustrate the “extreme rotation” out of the tech sector, and not to serve as a buy recommendation on Nvidia’s stock.After all, “history suggests Nvidia should modestly beat Eli Lilly over the next roughly two months, but bear in mind the chances of [Nvidia] outperforming is less than a coin flip historically,” she noted — as the actual win rate for Nvidia, when looking at instances where there was a positive forward 50-date return on a relative basis, has only been 44% since the start of 2010.Rabe also examined the recent performance of the broader healthcare sector versus the broader tech sector. Zooming out, she flagged the healthcare sector’s “highly unusual” outperformance by more than two standard deviations, which also occurred on Nov. 25. In historical instances where that dynamic unfolded, the tech sector went on to deliver 11.3 points worth of outperformance in the following 50 days.“History strongly suggests U.S. large-cap healthcare is overbought relative to tech and the latter should outperform over the next roughly two months,” Rabe noted. While trends didn’t play out that way back in 2022, she implied the ongoing interest-rate-cutting cycle could benefit tech stocks nowadays.Wednesday’s price action, however, highlights a continuation of tech underperformance spurred by concerns about the health of the AI trade. Eli Lilly’s stock was off more than 1% in afternoon action, while Nvidia’s was down more than 3%.Eli Lilly’s stock has also topped Nvidia’s on a year-to-date basis, with the pharmaceutical company’s stock gaining 35% versus the chip maker’s 27% rise.","news_type":1,"symbols_score_info":{"LLY":2,"NVDA":2}},"isVote":1,"tweetType":1,"viewCount":31,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":35,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}